MetaCap

Aytu BioPharma (AYTU) vs NanoViricides (NNVC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed NanoViricides (NNVC) over the past year, gaining 32.3% versus a loss of 10.2%. Over five years, NNVC leads with a -76.5% price change compared with -93.2% for AYTU. NanoViricides is the larger company by market cap ($29.1 million vs $28.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%NNVC-10.24%
+50%+7%-37%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%NNVC-75.16%
+11%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus NNVC key metrics
MetricAYTUNNVC
Share price$2.66$1.14
Market cap$28.91M$29.13M
1-day change0.00%-2.56%
YTD return+2.31%+0.88%
1-year return+32.34%-10.24%
5-year return-93.21%-76.54%
Forward P/E17.16—
EPS (TTM)$-1.78$-0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M$0
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-8.22M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$1.93
52-week low$1.75$0.85
Distance from 52-week high-13.36%-40.93%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+263.53%+426.32%
Average volume141.18K356.86K
Shares outstanding10.87M25.55M
Employees757
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed NNVC by 42.6 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

AYTU vs NNVC FAQ

Which is bigger, Aytu BioPharma or NanoViricides?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $28.91M for Aytu BioPharma (AYTU).

Which stock has performed better over the past year, AYTU or NNVC?

AYTU returned +32.34% over the past 12 months, compared with -10.24% for NNVC (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and NanoViricides in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons